Bio-Techne price target lowered to $80 from $86 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Bio-Techne to $80 from $86 and keeps a Buy rating on the shares. Bio-Techne reported a challenging Q2 that was impacted by continued headwinds in BioPharma funding, customer inventory destocking, and ongoing challenges in China, the analyst tells investors in a research note. The firm sees potential for a reaccelerated growth story that would also come with improved margins.